Summary of Key Points

• Significant Decline in Net Profit: Gaush Meditech Ltd expects net profit for the six months ended June 30, 2026, to fall sharply to between RMB13.9 million and RMB16.7 million, compared to RMB35.9 million for the same period in 2025. This represents a year-on-year decrease of approximately 53.5% to 61.3%.
• Revenue Decline: The Group’s revenue is projected to be in the range of RMB541.5 million to RMB648.7 million, down by about 0.7% to 17.1% from RMB653.1 million in H1 2025.
• Key Contributing Factors:
  • Adverse impacts from shifts in market demand structure driven by national policies.
  • Termination of agency cooperation for overseas femtosecond laser-assisted cataract surgery products, leading to reduced product distribution revenue.
  • Increased foreign exchange losses, estimated to rise by RMB7.8 million to RMB9.8 million over the previous year due to exchange rate fluctuations.
• Unaudited Results: The reported financials are based on management’s preliminary review of unaudited accounts and remain subject to review by auditors and the audit committee.
• Investor Caution Advised: Investors are urged to exercise caution in trading Gaush Meditech shares until the official interim results (expected by end of August 2026) are released.

Detailed Analysis

Gaush Meditech Ltd, a company listed on the Hong Kong Stock Exchange (stock code: 2407), has issued a profit warning for the first half of 2026. According to the company’s announcement, the Board anticipates a substantial decline in profit, forecasting a net profit of approximately RMB13.9 million to RMB16.7 million for H1 2026, compared to RMB35.9 million in the same period of the previous year. This dramatic drop—between 53.5% and 61.3%—is expected to be a significant concern for shareholders and could have a material impact on the company’s share price.

The expected revenue for H1 2026 is also lower, estimated at RMB541.5 million to RMB648.7 million, compared to RMB653.1 million in H1 2025. While this represents a relatively modest decline of 0.7% to 17.1%, the drop in profit is far more pronounced, suggesting that increased costs or other negative factors are at play.

The company attributes this profit decline to two primary factors:

1. Market-Driven Revenue Pressure: There has been a shift in market demand structure, influenced by changes in national policies, which has negatively affected the company’s business. In addition, the termination of agency agreements for overseas femtosecond laser-assisted cataract surgery products has led to a decline in product distribution revenue, further impacting the top line.
2. Foreign Exchange Losses: The company expects foreign exchange losses to increase by RMB7.8 million to RMB9.8 million compared to the same period last year, owing to exchange rate fluctuations. This has further eroded profitability.

As of the date of the announcement (July 23, 2026), Gaush Meditech Ltd is still in the process of finalizing its consolidated interim results for the six months ended June 30, 2026. The figures shared are based on a preliminary review of unaudited management accounts and may be subject to change following the audit committee’s and external auditors’ review.

The company has urged shareholders and investors to exercise caution when trading shares, as the official interim results will not be published until the end of August 2026. Given the magnitude of the profit decline and the identified adverse factors, this announcement is highly price-sensitive and could potentially trigger significant share price volatility.

Board Composition

The Board of Gaush Meditech Ltd currently comprises Mr. Gao Tieta (Chairman and executive Director), Mr. Liu Xinwei, Mr. Zhao Xinli, Mr. Zhang Jianjun, and Ms. Li Wenqi as executive Directors; Dr. David Guowei Wang as non-executive Director; and Ms. Cheng Juan, Mr. Yubing Li, and Ms. Qiu Xiaoling as independent non-executive Directors.

Conclusion

The profit warning issued by Gaush Meditech Ltd for H1 2026 signals a challenging period for the company, with both revenue and net profit falling sharply due to structural market changes and currency volatility. Investors should closely monitor the company’s upcoming interim results and exercise caution in trading its shares in the near term.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should refer to the official company announcements and consult with professional advisors before making investment decisions.

高視醫療集團有限公司2026年上半年盈利警告：投資者必讀詳情（廣東話版）

重點摘要

• 盈利大幅下跌： 高視醫療預計2026年上半年淨利潤僅為人民幣1,390萬元至1,670萬元，較2025年同期的人民幣3,590萬元下跌約 53.5%至61.3%。
• 收入下降： 預計2026年上半年收入為人民幣5.415億元至6.487億元，較2025年同期的人民幣6.531億元下降約 0.7%至17.1%。
• 主要原因：
  • 受國家政策推動市場需求結構變化影響，對業務構成壓力。
  • 海外飛秒激光輔助白內障手術產品代理合作終止，產品分銷收入下跌。
  • 受匯率波動影響，預計外匯損失同比增加人民幣780萬至980萬元。
• 未經審核結果： 公佈的數據基於管理層對未經審核帳目的初步審閱，最終財務數據尚待審計委員會及外部審計師審核。
• 建議投資者謹慎： 公司提醒投資者在正式中期業績（預計2026年8月底）公佈前，謹慎買賣公司股份。

詳細分析

高視醫療（港交所股份代號：2407）發佈2026年上半年盈利警告，預計公司期內盈利大幅下降，或對公司股價造成重大影響。管理層預期2026年上半年淨利潤僅為人民幣1,390萬元至1,670萬元，較去年同期的人民幣3,590萬元大幅下跌，跌幅達53.5%至61.3%。收入亦預計下降至人民幣5.415億元至6.487億元，與去年同期相比減少0.7%至17.1%。

公司表示，盈利下跌主要由於兩大因素：

1. 市場結構變動及收入壓力： 受國家政策帶動市場需求結構轉變，以及海外飛秒激光白內障手術產品代理合作終止，導致產品分銷收入減少。
2. 外匯損失增加： 因匯率波動，預計2026年上半年外匯損失較去年同期增加人民幣780萬至980萬元，進一步蠶食盈利。

截至公告日（2026年7月23日），公司仍在最終核實2026年上半年合併業績。現有數據僅屬管理層初步審閱，仍有待審計委員會及外部審計師進一步審核，數據或有調整。

公司強調，投資者應於正式中期業績公佈（預計於2026年8月底）前謹慎買賣公司股份。考慮到盈利大幅下跌及多項不利因素，公告具高度敏感性，或引起股價顯著波動。

董事會組成

現時董事會成員包括主席兼執行董事高鐵塔先生，執行董事劉新偉、趙新立、張建軍及李文淇，非執行董事王國偉博士，以及獨立非執行董事程娟、李玉兵、邱曉玲。

總結

高視醫療2026年上半年盈利警告反映公司正面臨嚴峻挑戰，收入及盈利大幅下滑。投資者應密切留意公司即將公佈的中期業績，並審慎作出投資決定。

免責聲明： 本文僅供資訊參考，並不構成任何投資建議。投資者應參考公司正式公告及諮詢專業顧問後作出投資決定。

View GAUSH MEDITECH Historical chart here